Document is current
Any future updates will be listed below
-
Authors
Renner, Alexander
Stahringer, Anika
Ruppel, Katharina Eva
Fricke, Stephan
Koehl, Ulrike https://orcid.org/0000-0002-8159-9160
Schmiedel, Dominik https://orcid.org/0000-0003-3384-5651
-
Funding
Funding for this research was provided by:
Fraunhofer-Gesellschaft (131-600004)
- License Information
-
More Information
Article History
Received: 11 October 2023
Revised: 15 April 2024
Accepted: 18 April 2024
First Online: 29 April 2024
Competing interests
: DS, AR, UK, SF filed the patent “koala retrovirus envelope glycoproteins and uses thereof” (PCT/EP2022/081009). All other authors declare no conflict of interest. SF: consultant and/or speaker fees from Novartis Pharma GmbH, Janssen-Cilag GmbH, Vertex Pharmaceuticals (Germany) GmbH, Kite/Gilead Sciences GmbH, MSGO GmbH, and Bristol-Myers Squibb GmbH & Co. KGaA. UK: Consultant and/or speaker fees: AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. KGaA.
